- Home
- QNCX vs KZIA Comparison
QNCX vs KZIA Comparison
Compare QNCX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | KZIA |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 93.2M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | QNCX | KZIA |
|---|---|---|
| Price | $0.11 | $8.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $10.00 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 128.8M | 201.8K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.64 |
| 52 Week High | $4.55 | $17.40 |
Technical Indicators
Market Signals| Indicator | QNCX | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 28.02 | 54.36 |
| Support Level | $0.09 | $7.54 |
| Resistance Level | $0.98 | $8.17 |
| Average True Range (ATR) | 0.02 | 1.09 |
| MACD | 0.09 | 0.10 |
| Stochastic Oscillator | 26.32 | 49.69 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.